Your browser doesn't support javascript.
loading
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing, Luisa Maria; Schweizer, Claudia; Schubert, Philipp; Rutzner, Sandra; Eckstein, Markus; Frey, Benjamin; Haderlein, Marlen; Weissmann, Thomas; Semrau, Sabine; Gostian, Antoniu-Oreste; Müller, Sarina K; Traxdorf, Maximilian; Iro, Heinrich; Zhou, Jian-Guo; Gaipl, Udo S; Fietkau, Rainer; Hecht, Markus.
Afiliação
  • Griewing LM; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Schweizer C; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Schubert P; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Rutzner S; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Eckstein M; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Frey B; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Haderlein M; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Weissmann T; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Semrau S; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Gostian AO; Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Müller SK; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Traxdorf M; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Iro H; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Zhou JG; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Gaipl US; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
  • Fietkau R; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Hecht M; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
BMC Cancer ; 21(1): 314, 2021 Mar 24.
Article em En | MEDLINE | ID: mdl-33761922
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitoramento de Medicamentos / Autorrelato / Quimiorradioterapia / Inibidores de Checkpoint Imunológico / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitoramento de Medicamentos / Autorrelato / Quimiorradioterapia / Inibidores de Checkpoint Imunológico / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article